October 25, 2021
Background: Some authors have reported positive associations between B-cell-depleting (anti-CD20) therapies and COVID-19 infection risk or...
Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....
3 University Plaza Drive, Ste 116Hackensack, NJ 07601
© 2021 CMSC